Personalized treatment for children with relapsed or resistant AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial offers a personalized treatment plan for children with hard-to-treat or relapsed acute myeloid leukemia (AML). The plan is based on the unique genetic makeup of the child's cancer and lab tests that find the most effective drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is under 18 years old.
- Has acute myeloid leukemia (AML) that came back after treatment or didn't fully respond to at least two treatments.
- Has good organ function (heart, kidneys, etc.) and can safely receive chemotherapy.
- Does not have certain other types of leukemia or conditions like Down syndrome or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies different treatment plans for children and teens newly diagnosed with AML (a type of blood cancer). Depending on the child's tumor markers and risk group, they may be offered an extra drug (quizartinib) or a targeted antibody (Mylotarg) to see if it improves outcomes.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
This trial uses a special lab test (pharmacoscopy) to help your doctor choose the best standard chemotherapy for your AML. It is for people whose leukemia has returned or not responded to treatment, and who are strong enough for intensive chemotherapy.
This study tests a treatment plan for children under 18 with a new diagnosis of acute myeloid leukemia (AML). It aims to provide effective therapy based on standard guidelines, and may include children with certain blood or bone marrow findings even if tests are limited.
This trial tests a new cell therapy (BG1805) for children whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The therapy targets a specific marker on leukemia cells called CLL-1 and aims to help the immune system fight the cancer.
Hear when a new Acute Myeloid Leukemia in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.